By Amrutha Penumudi (Reuters) - Shares of Auspex Pharmaceuticals Inc soared about 60 percent on Tuesday after the drug developer said its product for treating chorea, or involuntary movement associated with Huntington's disease, met the main goal in a late-stage study. The shares jumped about to $40 in extended trading after closing at $25.09 on Nasdaq. Patients administered SD-809, Auspex's lead drug, showed an improvement in a standardized score measuring involuntary movement, compared with those given a placebo. ...
via Health News Headlines - Yahoo News http://ift.tt/1BUbIxO
via Health News Headlines - Yahoo News http://ift.tt/1BUbIxO
No comments:
Post a Comment